Actuate Therapeutics Inc
ACTUHealthcare·Biotechnology·USA·Nano·NASD·Nov 13 • 7:58 AM ET
0.30+0.00 (0.68%)
2026-11-13 14:04 CET
Market cap
$16.36M
Revenue, TTM
0.00 USD m
Net income, TTM
-20.45 USD m
Free cash flow, TTM
-19.66 USD m
EPS diluted, TTM
-0.89
Price
ACTU against its 20, 50 and 200-day averagesPatternshover a marker to name it
96.2% under the 52-week high of 7.90 on 10 Dec 2025. 52-week low 0.29 on 10 Nov 2026. Last 15 sessions, 106.9% high to low
Volume 0.02× normal · the line is the 50-bar volume average
Setup. RS line 0
CANSLIM 3 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 0 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 2 of 4 — fails: EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 1 of 5 — fails: Return on Equity: Over +15%; Debt/Equity: Low (<0.1) — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 0 of 4 — fails: P/B: Under 2; Return on Equity: Over +15%; Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Average Volume: Over 500K; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 0 of 4 — fails: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 0 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200; Average Volume: Over 500K
Profile
ACTU52-week range, 0% of the way up
0.297.90
Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.
| Employees | 12 |
|---|---|
| IPO | Aug 13, 2024 |
| Beta | 1.54 |
| ATR, 14d | 0.08 |
| Rel volume | 0.02 |
| Short float | 12.69% |
| Insider own | 57.42% |
| Inst own | 14.07% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | $16.36M |
| Enterprise Value | 12.33M |
| Income | -20.45M |
| Sales | 0.00M |
| Book / share | 0.04 |
| Cash / share | 0.08 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 12 |
| IPO | Aug 13, 2024 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | - |
| Price / book | 7.22 |
| Price / cash | 3.69 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | - |
| Quick Ratio | 1.25 |
| Current Ratio | 1.25 |
| Debt / equity | 0.40 |
| Long-term debt / equity | 0.40 |
| Options and short | No / Yes |
Earnings
| Earnings / share | -0.89 |
|---|---|
| Earnings next year | -0.66 |
| Earnings next quarter | -0.17 |
| Earnings this year | 31.45% |
| Earnings next year | 8.72% |
| Earnings growth, 5 years | 13.33% |
| Past earnings growth | -0.08% - |
| Past sales growth | - - |
| Earnings vs last year | 29.39% |
| Sales vs last year | - |
| Earnings vs last quarter | 32.66% |
| Sales vs last quarter | - |
| Earnings | Sep 02 |
| Surprise | 1.62% - |
Ownership
| Insiders own | 57.42% |
|---|---|
| Insider trades | 0.45% |
| Institutions own | 14.07% |
| Institution trades | -1.23% |
| Return on assets | -336.18% |
| Return on equity | -553.75% |
| Return on capital | -1467.12% |
| Gross Margin | - |
| Operating margin | - |
| Profit Margin | - |
| 20-day average | -25.71% |
| 50-day average | -55.37% |
| 200-day average | -84.39% |
Technical
| Shares out | 24.01M |
|---|---|
| Shares floating | 10.23M |
| Short / float | 12.69% |
| Short ratio | 3.08 |
| Short interest | 1.30M |
| 52-week high | 7.90 -96.2% |
| 52-week low | 0.29 +2.8% |
| Volatility | 16.87% 20.01% |
| Average range | 0.08 |
| Strength index | 31.49 |
| Market sensitivity | 1.54 |
| Relative volume | 0.02 |
| Avg Volume | 421.84K |
| Volume | 465 |
Performance
| Perf Week | -9.52% |
|---|---|
| Perf Month | -40.49% |
| Perf Quarter | -69.95% |
| Perf Half Y | -88.65% |
| Perf YTD | -95.14% |
| Perf Year | -94.94% |
| Perf 3Y | - |
| Perf 5Y | - |
| Perf 10Y | - |
| Recommendation | 1.00 |
| Target Price | 10.25 |
| Prev Close | 0.30 |
| Price | 0.30 |
| Change % | 0.51% |
Analyst ratings
latest 3 of 3| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Aug 26, 2025 | Initiated | B. Riley Securities | Buy | $20 | +6,622.7% |
| Apr 22, 2025 | Initiated | Craig Hallum | Buy | $21 | +6,958.8% |
| Mar 17, 2025 | Initiated | H.C. Wainwright | Buy | $20 | +6,622.7% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| LSTA | Lisata Therapeutics Inc | 13.83M |
| ELTX | Elicio Therapeutics Inc | 44.16M |
| ONCY | Oncolytics Biotech Inc | 48.82M |
| CRDF | Cardiff Oncology Inc | 56.60M |
| RVMD | Revolution Medicines Inc | 38.23B |
| VSTM | Verastem Inc | 1.05B |
| TPST | Tempest Therapeutics Inc | 8.00M |
| KZIA | Kazia Therapeutics Limited ADR | 79.55M |
| PMVP | PMV Pharmaceuticals Inc | 91.40M |
| RFL | Rafael Holdings Inc | 57.94M |
Insider trading
5 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| SCHMITT DANIEL M | President, CEO and Director | Oct 28 '26 | Buy | 0.35 | 140,844 | 50,000 | 442,560 | Oct 29 09:35 AM |
| SCHMITT DANIEL M | President, CEO and Director | Aug 14 '26 | Option Exercise | 0.00 | 272,056 | 0 | 422,237 | Aug 14 05:00 PM |
| SCHMITT DANIEL M | President, CEO and Director | Feb 13 '26 | Option Exercise | 0.00 | 272,055 | 0 | 272,055 | Feb 13 06:10 PM |
| THOMSON TODD S | Director | Jan 05 '26 | Sale | 5.80 | 280,000 | 1,624,000 | 904,795 | Jan 07 12:45 PM |
| Kairos Venture Partners II, L. | Affiliate | Dec 11 '25 | Proposed Sale | 7.60 | 280,000 | 2,128,000 | Dec 11 04:22 PM |
Held by
AUMNews
latest 14 of 116- Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026 (GlobeNewswire) +5.69%
- Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral Tablets (GlobeNewswire)
- Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering (GlobeNewswire) -24.32%
- Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire) -8.03% -8.73%
- Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib (GlobeNewswire)
- Actuate Therapeutics' Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma (GlobeNewswire) +10.44%
- Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer (GlobeNewswire)
- Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program (GlobeNewswire) -9.85%
- Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors (GlobeNewswire)
- Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire) +14.29%
- Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers (ACCESSWIRE) -9.43%
- Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors (GlobeNewswire)
- Actuate Therapeutics to Present at The Citizens Life Sciences Conference (GlobeNewswire)
- Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire) +10.64%
Quarterly earnings
2026Q2 EPS -0.200 beat -0.203, from -0.300 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q2ended 2026-06-30 | 2026-09-02 12:00 | -0.200 | -0.203 | -0.200 | 0.00 | 0.00 | EPS -1.6% · sales - | vs 2025Q2, year-ago quarter · EPS -33.3% · sales - | 3 EPS · 2 sales | Open -2.60% vs SPY +0.09%. Close -15.58% vs SPY +0.44% |
| 2026Q1ended 2026-03-31 | 2026-06-03 12:00 | -0.240 | -0.240 | -0.240 | 0.00 | 0.00 | EPS 0.0% · sales - | vs 2025Q1, year-ago quarter · EPS -25.0% · sales - | 4 EPS · 3 sales | Open +0.53% vs SPY -0.19%. Close -3.19% vs SPY -0.70% |
| 2025Q4ended 2025-12-31 | 2026-02-25 12:00 | -0.198 | -0.244 | -0.196 | 0.00 | 0.00 | EPS -19.1% · sales - | vs 2024Q4, year-ago quarter · EPS -40.2% · sales - | 3 EPS · 2 sales | Open +0.48% vs SPY +0.41%. Close -2.40% vs SPY +0.84% |
| 2025Q3ended 2025-09-30 | 2025-12-03 12:00 | -0.251 | -0.263 | -0.253 | 0.00 | 0.00 | EPS -4.7% · sales - | vs 2024Q3, year-ago quarter · EPS -54.4% · sales - | 3 | Open +0.41% vs SPY -0.14%. Close +1.36% vs SPY +0.35% |
| 2025Q2ended 2025-06-30 | 2025-09-03 12:00 | -0.300 | -0.300 | -0.303 | 0.00 | 0.00 | EPS 0.0% · sales - | vs 2024Q2, year-ago quarter · EPS -92.9% · sales - | 4 EPS · 3 sales | Open +0.57% vs SPY +0.37%. Close -1.03% vs SPY +0.54% |
| 2025Q1ended 2025-03-31 | 2025-05-28 12:00 | -0.320 | -0.300 | -0.324 | 0.00 | 0.00 | EPS +6.7% · sales - | - | 3 | Open +1.36% vs SPY +0.07%. Close +4.66% vs SPY -0.58% |
| 2024Q4ended 2024-12-31 | 2025-02-26 12:00 | -0.330 | -0.290 | -0.330 | 0.00 | 0.00 | EPS +13.8% · sales - | - | 1 | Open +2.41% vs SPY +0.28%. Close -0.42% vs SPY +0.05% |
| 2024Q3ended 2024-09-30 | 2024-11-27 12:00 | -0.550 | -0.550 | -0.306 | 0.00 | 0.00 | EPS 0.0% · sales - | - | 1 | Open +3.78% vs SPY -0.03%. Close -3.56% vs SPY -0.30% |
| 2024Q2ended 2024-06-30 | 2024-08-28 12:00 | -4.200 | - | -0.337 | 0.00 | - | EPS - · sales - | - | - | Open +0.12% vs SPY -0.06%. Close -0.87% vs SPY -0.58% |
| 2026Q3ended 2026-09-30 | - | - | -0.170 | - | - | 0.00 | EPS - · sales - | vs 2025Q3, year-ago quarter · EPS - · sales - | 3 EPS · 2 sales | - |
| 2026Q4ended 2026-12-31 | - | - | -0.170 | - | - | 0.00 | EPS - · sales - | vs 2025Q4, year-ago quarter · EPS - · sales - | 3 EPS · 2 sales | - |
| 2027Q1ended 2027-03-31 | - | - | -0.170 | - | - | 0.00 | EPS - · sales - | vs 2026Q1, year-ago quarter · EPS - · sales - | 3 EPS · 2 sales | - |
| 2027Q2ended 2027-06-30 | - | - | -0.167 | - | - | 0.00 | EPS - · sales - | vs 2026Q2, year-ago quarter · EPS - · sales - | 3 EPS · 2 sales | - |
| 2027Q3ended 2027-09-30 | - | - | -0.167 | - | - | 0.00 | EPS - · sales - | vs 2026Q3, year-ago quarter · EPS - · sales - | 3 EPS · 2 sales | - |
| 2027Q4ended 2027-12-31 | - | - | -0.160 | - | - | 0.00 | EPS - · sales - | vs 2026Q4, year-ago quarter · EPS - · sales - | 3 EPS · 2 sales | - |
Annual earnings
2025FY EPS -1.060 beat -1.078, from -3.260 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | 1.280 | - | - | 102.07 | 0.23 |
| 2029FYestimate | - | -0.193 | - | - | 48.30 | - |
| 2028FYestimate | - | -0.690 | - | - | - | - |
| 2027FYestimate | - | -0.663 | - | - | 0.00 | - |
| 2026FYestimate | - | -0.727 | - | - | 0.00 | - |
| 2025FY | -1.060 | -1.078 | -1.060 | 0.00 | 0.00 | - |
| 2024FY | -3.260 | -3.160 | -1.397 | 0.00 | 0.00 | - |
Quarterly results
2026Q2 revenue 0.00, from 0.00 a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -0.73 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-10-31 | -0.73 | 0.0% |
| 2026Q3 | E | per share | 2026-10-31 | -0.17 | 0.0% |
| 2026FY | R | per share | 2026-10-28 | -0.72 | 0.0% |
| 2026Q3 | R | per share | 2026-09-02 | -0.15 | 0.0% |
| 2026Q3 | S | per share | 2026-09-02 | 0.00 | - |
| 2026Q2 | E | per share | 2026-08-22 | -0.20 | -3.2% |
| 2026FY | S | per share | 2026-08-22 | 0.00 | - |
| 2026Q2 | S | per share | 2026-08-22 | 0.00 | - |
| 2026Q2 | R | per share | 2026-08-14 | -0.20 | +33.3% |
| 2026Q1 | E | per share | 2026-05-15 | -0.24 | +7.9% |
| 2026Q1 | R | per share | 2026-05-15 | -0.24 | +20.0% |
| 2026Q1 | S | per share | 2026-04-10 | 0.00 | - |
| 2025FY | E | per share | 2026-02-20 | -1.08 | -1.2% |
| 2025Q4 | E | per share | 2026-02-20 | -0.24 | -0.6% |
| 2025FY | S | per share | 2026-02-20 | 0.00 | - |
| 2025Q4 | S | per share | 2026-02-20 | 0.00 | - |
| 2025FY | R | per share | 2026-01-05 | -1.12 | -8.2% |
| 2025Q4 | R | per share | 2026-01-05 | -0.25 | -16.7% |
| 2025Q3 | E | per share | 2025-11-22 | -0.26 | -2.5% |
| 2025Q3 | R | per share | 2025-10-28 | -0.29 | 0.0% |
| 2025Q3 | S | per share | 2025-09-03 | 0.00 | - |
| 2025Q2 | E | per share | 2025-08-22 | -0.30 | 0.0% |
| 2025Q2 | S | per share | 2025-08-15 | 0.00 | - |
| 2025Q2 | R | per share | 2025-08-14 | -0.30 | +3.4% |
| 2025Q1 | E | per share | 2025-05-19 | -0.30 | +1.1% |
| 2025Q1 | R | per share | 2025-05-19 | -0.32 | +3.2% |
| 2025Q1 | S | per share | 2025-05-05 | 0.00 | - |
| 2024Q4 | E | per share | 2024-11-27 | -0.29 | 0.0% |
| 2024Q4 | S | per share | 2024-11-27 | 0.00 | - |
| 2024Q3 | E | per share | 2024-11-13 | -0.55 | +89.7% |
| 2024Q3 | S | per share | 2024-11-13 | 0.00 | - |
Estimate history
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|
| EPS per share | -1.055 | -1.295 | -1.397 | -1.057 | -0.8915 | - |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | - |
| Shares million shares | 19 | 19 | 20 | 23 | - | 24 |
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.337 | -0.306 | -0.33 | -0.324 | -0.303 | -0.253 | -0.196 | -0.239 | -0.204 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 20 | 20 | 20 | 20 | 20 | 23 | 23 | 24 | 24 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 |
|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling, General and Administrative Excl. Other | 20.77 | 22.49-10.6% | 25.16+0.8% | 24.97+23.6% | 20.21 |
| Research and Development | 8.94 | 10.29-44.9% | 18.68-14.0% | 21.71+32.5% | 16.39 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -20.77 | -22.49 | -25.16 | -24.97 | -20.21 |
| Interest Expense | 0.02 | 0.020.0% | 0.02-50.0% | 0.04+100.0% | 0.02 |
| Unusual Expense | 0.00 | 0.00-100.0% | 2.67+3237.5% | 0.08 | -0.04 |
| Net Income Before Taxes | -20.45 | -22.23 | -27.28 | -24.74 | -20.16 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -20.45 | -22.23 | -27.29 | -24.74 | -20.16 |
| Net Income From Continuing Operations | -20.45 | -22.23 | -27.29 | -24.74 | -20.16 |
| Net Income | -20.45 | -22.23 | -27.29 | -24.74 | -20.16 |
| EPS (Recurring) per share | -0.86 | -1.06 | -1.30 | -1.29 | -1.06 |
| EPS (Basic, Before Extraordinaries) per share | -0.89 | -1.06 | -1.40 | -1.29 | -1.05 |
| EPS (Diluted) per share | -0.89 | -1.06 | -1.40 | -1.29 | -1.05 |
| EBITDA | -20.77 | -22.49 | -25.16 | -24.97 | -20.21 |
| Non-Operating Income (Expense) | 0.34 | 0.29-49.1% | 0.57+62.9% | 0.35+1066.7% | 0.03 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 5.72 | 4.78+202.5% | 1.58+276.2% | 0.42-35.4% | 0.65 |
| Shares Outstanding million shares | 24.01 | 23.25+19.0% | 19.53+2.2% | 19.110.0% | 19.11 |
| Market Capitalization | 7.11 | 7.11-95.4% | 155.47-0.3% | 155.86 | - |
Income statement, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling, General and Administrative Excl. Other | 4.91-17.8% | 5.71-10.4% | 4.69-28.5% | 5.47+1.5% | 5.97+9.7% | 6.37-18.0% | 6.56-13.9% | 5.39-16.8% |
| Research and Development | 2.07-25.0% | 2.57-20.2% | 2.13-42.3% | 2.18-42.0% | 2.76-36.8% | 3.22-53.1% | 3.69-44.5% | 3.76-34.7% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -4.91 | -5.71 | -4.69 | -5.47 | -5.97 | -6.37 | -6.56 | -5.39 |
| Interest Expense | 0.010.0% | 0.010.0% | 0.010.0% | 0.01 | 0.010.0% | 0.010.0% | 0.010.0% | 0.00-100.0% |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 1.00 |
| Net Income Before Taxes | -4.87 | -5.63 | -4.55 | -5.41 | -5.95 | -6.32 | -6.45 | -5.97 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -4.87 | -5.63 | -4.55 | -5.41 | -5.95 | -6.32 | -6.45 | -5.97 |
| Net Income From Continuing Operations | -4.87 | -5.63 | -4.55 | -5.41 | -5.95 | -6.32 | -6.45 | -5.97 |
| Net Income | -4.87 | -5.63 | -4.55 | -5.41 | -5.95 | -6.32 | -6.45 | -5.97 |
| EPS (Recurring) per share | -0.20 | -0.24 | -0.20 | -0.25 | -0.30 | -0.32 | -0.33 | -0.27 |
| EPS (Basic, Before Extraordinaries) per share | -0.20 | -0.24 | -0.20 | -0.25 | -0.30 | -0.32 | -0.33 | -0.31 |
| EPS (Diluted) per share | -0.20 | -0.24 | -0.20 | -0.25 | -0.30 | -0.32 | -0.33 | -0.31 |
| EBITDA | -4.91 | -5.71 | -4.69 | -5.47 | -5.97 | -6.37 | -6.56 | -5.39 |
| Non-Operating Income (Expense) | 0.05+150.0% | 0.09+80.0% | 0.14+16.7% | 0.07-83.3% | 0.02+100.0% | 0.05+400.0% | 0.12+100.0% | 0.42+223.1% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 1.34-15.2% | 1.36+20.4% | 1.22+29.8% | 1.80+215.8% | 1.58+1655.6% | 1.13+653.3% | 0.94+683.3% | 0.57+256.2% |
| Shares Outstanding million shares | 24.01+17.3% | 23.71+21.4% | 23.25+19.0% | 23.24+19.0% | 20.47+4.8% | 19.53+2.2% | 19.53+2.2% | 19.530.0% |
| Market Capitalization | 7.11-94.1% | 64.97-50.9% | 142.25-8.5% | 155.50+9.2% | 119.88+0.0% | 132.23 | 155.47 | 142.38 |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 |
|---|---|---|---|---|
| Cash & Short Term Investments | 13.16+52.3% | 8.64+191.9% | 2.96-85.5% | 20.45 |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.48-15.8% | 0.57+1325.0% | 0.04+33.3% | 0.03 |
| Total Current Assets | 13.64+48.1% | 9.21+207.0% | 3.00-85.4% | 20.48 |
| Net Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | - | - | 0.00 | 0.00 |
| Other Assets | 0.39+254.5% | 0.11 | 0.00 | 0.00 |
| Total Assets | 14.04+50.6% | 9.32+210.7% | 3.00-85.4% | 20.48 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Accounts Payable | 1.52-20.8% | 1.92-43.9% | 3.42+60.6% | 2.13 |
| Other Current Liabilities | 4.18-39.2% | 6.88+96.6% | 3.50+58.4% | 2.21 |
| Total Current Liabilities | 5.71-35.1% | 8.80+27.2% | 6.92+59.4% | 4.34 |
| Long Term Debt | 0.400.0% | 0.400.0% | 0.400.0% | 0.40 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00-100.0% | 0.01-99.1% | 1.12+24.4% | 0.90 |
| Total Liabilities | 6.11-33.7% | 9.21+9.1% | 8.44+49.4% | 5.65 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00-100.0% | 94.18+4.5% | 90.14 |
| Common Equity | 7.92+7820.0% | 0.10 | -99.63 | -75.31 |
| Total Shareholders Equity | 7.92+7820.0% | 0.10 | -5.45-136.7% | 14.83 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 7.92+7820.0% | 0.10 | -5.45-136.7% | 14.83 |
| Total Liabilities & Stockholders Equity | 14.04+50.6% | 9.32+210.7% | 3.00-85.4% | 20.48 |
| Book Value Per Share per share | 0.34+3300.0% | 0.01 | -5.21 | -3.94 |
| Tangible Book Value Per Share per share | 0.34+3300.0% | 0.01 | -5.21 | -3.94 |
| Full-Time Employees people | 12+20.0% | 10 | - | - |
| Price to Book Ratio ratio | 7.19 | 29.01 | 29.09 | - |
| Return on Assets % | -190.35 | -443.16 | -210.78 | - |
| Return on Equity % | -553.75 | - | -527.37 | - |
| Return on Invested Capital % | -266.87 | -5,358.71 | - | -132.30 |
| Quick Ratio ratio | 2.39 | 1.05 | 0.43 | 4.71 |
| Current Ratio ratio | 2.39 | 1.05 | 0.43 | 4.71 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 |
|---|---|---|---|---|---|
| Net Income | -20.45 | -22.23 | -27.29 | -24.74 | -20.16 |
| Other Funds (Non Cash) | 6.37 | 6.07+39.9% | 4.34+689.1% | 0.55-12.7% | 0.63 |
| Funds from Operations | -14.08 | -16.16 | -22.94 | -24.20 | -19.53 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -5.58 | -3.05-377.3% | 1.10-57.2% | 2.57+48.6% | 1.73 |
| Cash from Operating Activities | -19.66 | -19.21 | -21.84 | -21.63 | -17.79 |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 18.42 | 24.03+9.1% | 22.03+433.4% | 4.13-78.6% | 19.26 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 18.42 | 24.03+9.1% | 22.03+433.4% | 4.13-78.6% | 19.26 |
| Proceedsfrom Stock Options | 18.42 | 23.99+8.9% | 22.03+433.4% | 4.13-78.6% | 19.26 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00-100.0% | 5.50 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | -0.83 | -0.30 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | -0.83 | -0.30 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 17.59 | 23.72-13.8% | 27.53+566.6% | 4.13-78.6% | 19.26 |
| Net Change in Cash | -2.07 | 4.52-20.4% | 5.68 | -17.49-1297.9% | 1.46 |
| Free Cash Flow | -19.66 | -19.21 | -21.84 | -21.63 | -17.79 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 4.43-31.7% | 8.13+109.0% | 13.16+52.3% | 16.92+25.1% | 6.49+1754.3% | 3.89+87.9% | 8.64+191.9% | 13.52 |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.32+60.0% | 0.39+8.3% | 0.48-15.8% | 0.52-29.7% | 0.200.0% | 0.36+200.0% | 0.57+1325.0% | 0.74 |
| Total Current Assets | 4.75-29.0% | 8.52+100.5% | 13.64+48.1% | 17.44+22.3% | 6.69+1116.4% | 4.25+94.1% | 9.21+207.0% | 14.26 |
| Net Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | - | - | - | - | - | - | - | 0.00 |
| Other Assets | 0.45+60.7% | 0.39+69.6% | 0.39+254.5% | 0.27 | 0.28-76.3% | 0.23-54.9% | 0.11 | 0.00 |
| Total Assets | 5.20-25.4% | 8.91+98.9% | 14.04+50.6% | 17.71+24.2% | 6.97+302.9% | 4.48+65.9% | 9.32+210.7% | 14.26 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00 | 0.00 |
| Accounts Payable | 1.08-65.9% | 1.20-54.5% | 1.52-20.8% | 1.25-46.4% | 3.17-46.2% | 2.64-33.3% | 1.92-43.9% | 2.33 |
| Other Current Liabilities | 2.73-54.7% | 3.52-45.9% | 4.18-39.2% | 5.13-16.9% | 6.03-17.2% | 6.51+12.6% | 6.88+96.6% | 6.17 |
| Total Current Liabilities | 3.81-58.6% | 4.72-48.4% | 5.71-35.1% | 6.37-25.1% | 9.20-54.2% | 9.15-37.9% | 8.80+27.2% | 8.50 |
| Long Term Debt | 0.400.0% | 0.400.0% | 0.400.0% | 0.400.0% | 0.400.0% | 0.400.0% | 0.400.0% | 0.40 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.00 | 0.02-98.5% | 0.01-99.1% | 0.01-99.1% | 0.00 |
| Total Liabilities | 4.21-56.2% | 5.13-46.4% | 6.11-33.7% | 6.78-23.8% | 9.62-55.9% | 9.57-41.3% | 9.21+9.1% | 8.90 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.00 |
| Common Equity | 0.99 | 3.78 | 7.92+7820.0% | 10.94+104.1% | -2.65 | -5.09 | 0.10 | 5.36 |
| Total Shareholders Equity | 0.99 | 3.78 | 7.92+7820.0% | 10.94+104.1% | -2.65 | -5.09 | 0.10 | 5.36 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 0.99 | 3.78 | 7.92+7820.0% | 10.94+104.1% | -2.65 | -5.09 | 0.10 | 5.36 |
| Total Liabilities & Stockholders Equity | 5.20-25.4% | 8.91+98.9% | 14.04+50.6% | 17.71+24.2% | 6.97+302.9% | 4.48+65.9% | 9.32+210.7% | 14.26 |
| Book Value Per Share per share | 0.04 | 0.16 | 0.34+3300.0% | 0.47+74.1% | -0.13 | -0.26 | 0.01 | 0.27 |
| Tangible Book Value Per Share per share | 0.04 | 0.16 | 0.34+3300.0% | 0.47+74.1% | -0.13 | -0.26 | 0.01 | 0.27 |
| Full-Time Employees people | - | - | 12+20.0% | - | - | - | 10 | - |
| Price to Book Ratio ratio | 7.19 | 8.04 | 13.01 | -51.60 | -23.46 | 1,270.17 | 29.01 | -1.27 |
| Return on Assets % | -336.18 | -321.58 | -190.35 | -150.86 | -567.45 | -704.75 | -443.16 | - |
| Return on Equity % | - | - | -553.75 | -296.04 | - | - | - | - |
| Return on Invested Capital % | -349.08 | -134.29 | -54.68 | -47.68 | - | - | -1,265.98 | -103.60 |
| Quick Ratio ratio | 1.25 | 1.80 | 2.39 | 2.74 | 0.73 | 0.46 | 1.05 | 1.68 |
| Current Ratio ratio | 1.25 | 1.80 | 2.39 | 2.74 | 0.73 | 0.46 | 1.05 | 1.68 |
Cash flow, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -4.87 | -5.63 | -4.55 | -5.41 | -5.95 | -6.32 | -6.45 | -5.97 |
| Other Funds (Non Cash) | 1.35-4.3% | 1.50+32.7% | 1.55+29.2% | 1.98+40.4% | 1.41+18.5% | 1.13+109.3% | 1.20+566.7% | 1.41+907.1% |
| Funds from Operations | -3.52 | -4.13 | -3.01 | -3.43 | -4.54 | -5.19 | -5.25 | -4.56 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -0.88-563.2% | -0.89-256.1% | -0.73-252.1% | -3.08 | 0.19-92.9% | 0.57-75.8% | 0.48-75.0% | -4.40-885.7% |
| Cash from Operating Activities | -4.41 | -5.02 | -3.74 | -6.50 | -4.35 | -4.62 | -4.77 | -8.96 |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.70-89.9% | 0.52 | 0.00 | 17.21-22.3% | 6.95 | -0.13 | -0.11 | 22.14 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.70-89.9% | 0.52 | 0.00 | 17.21-22.3% | 6.95 | -0.13 | -0.11 | 22.14 |
| Proceedsfrom Stock Options | 0.70-89.9% | 0.52 | 0.00 | 17.21-22.3% | 6.92 | -0.13 | -0.11 | 22.14 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | -0.53 | -0.03 | -0.27 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | -0.53 | -0.03 | -0.27 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 0.70-89.9% | -0.01 | -0.03 | 16.93-23.5% | 6.95+595.0% | -0.13-102.9% | -0.11 | 22.14 |
| Net Change in Cash | -3.71-242.7% | -5.03 | -3.77 | 10.43-20.8% | 2.60 | -4.75 | -4.88 | 13.17 |
| Free Cash Flow | -4.41 | -5.02 | -3.74 | -6.50 | -4.35 | -4.62 | -4.77 | -8.96 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 12.69% | 1.3M | 10.2M | 410.57K |
| 2026-10-15 | 18.26% | 1.9M | 10.2M | 327.73K |
| 2026-09-30 | 13.00% | 1.3M | 10.2M | 375.67K |
| 2026-09-15 | 10.73% | 1.1M | 10.2M | 368.33K |
| 2026-08-31 | 11.46% | 1.2M | 10.2M | 344.72K |
| 2026-08-14 | 6.84% | 0.7M | 10.2M | 258.99K |
| 2026-07-31 | 4.37% | 0.5M | 10.3M | 250.33K |
| 2026-07-15 | 7.33% | 0.8M | 10.3M | 268.44K |
| 2026-06-30 | 6.68% | 0.7M | 10.3M | 179.47K |
| 2026-06-15 | 8.90% | 0.9M | 10.3M | 162.31K |
| 2026-05-29 | 9.05% | 0.9M | 10.2M | 145.53K |
| 2026-05-15 | 8.68% | 0.9M | 10.2M | 134.70K |
| 2026-04-30 | 9.41% | 0.9M | 10.1M | 119.06K |
| 2026-04-15 | 9.09% | 0.9M | 10.1M | 88.79K |
| 2026-03-31 | 6.60% | 0.7M | 9.9M | 73.33K |
| 2026-03-13 | 6.90% | 0.7M | 9.7M | 74.00K |
| 2026-02-27 | 6.61% | 0.6M | 9.7M | 74.68K |
| 2026-02-13 | 6.55% | 0.6M | 9.7M | 80.21K |
| 2026-01-30 | 6.24% | 0.6M | 9.9M | 78.75K |
| 2026-01-15 | 5.40% | 0.5M | 9.9M | 77.35K |
Option chain
Expiry 2026-11-13 · underlying 0.30, quoted 13 Nov 07:58 ET · ATM -
Option quotes -. A date on a row is older than the last session (12 Nov). 0 rows.
Implied move — the ATM straddle is not quoted.
Put/call open interest — no calls · Put/call volume — no calls
IV change is points against the prior close.
| Type | Strike | Money | Bid | Ask | Last | Chg | IV | Open int | Volume | Last size | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | |||||||||||||
Latest SEC filings
30 of 192AllAll annual, quarterly, and current reportsInsider equity awards, transactions, and ownership (Section 16 Reports)Beneficial ownership reportsExempt offeringsRegistration statements and prospectusesFiling review correspondenceSEC orders and noticesProxy materialsTender offers and going private transactionsTrust indenture filings
10-Q filed 2026-08-14, period ended 2026-06-30. 10-K filed 2026-03-26, period ended 2025-12-31. ACTU on EDGAR
page 1 of 7Next →
| Filed | Form | Description | Period | Document |
|---|---|---|---|---|
| 2026-11-02 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-10-28 · transaction | 0001193125-26-443732 index |
| 2026-10-30 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-10-30 · transaction | 0001791917-26-000006 index |
| 2026-10-30 | SCHEDULE 13G | Beneficial ownership reports | no report period | 0001753926-26-002033 index |
| 2026-10-30 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-10-28 · transaction | 0001697316-26-000014 index |
| 2026-10-30 | 8-K | All annual, quarterly, and current reports | 2026-10-28 | 0001683168-26-008193 index |
| 2026-10-29 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-10-28 · transaction | 0001683168-26-008147 index |
| 2026-10-28 | 8-K | All annual, quarterly, and current reports | 2026-10-26 | 0001683168-26-008143 index |
| 2026-10-28 | 424B5 | Registration statements and prospectuses | no report period | 0001683168-26-008122 index |
| 2026-10-26 | EFFECT | SEC orders and notices | no report period | 9999999995-26-003345 index |
| 2026-10-19 | S-1/A | Registration statements and prospectuses | no report period | 0001683168-26-007941 index |
| 2026-10-14 | S-1/A | Registration statements and prospectuses | no report period | 0001683168-26-007832 index |
| 2026-10-08 | FWP | Registration statements and prospectuses | no report period | 0001683168-26-007710 index |
| 2026-10-06 | S-1 | Registration statements and prospectuses | no report period | 0001683168-26-007661 index |
| 2026-08-14 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-08-14 · transaction | 0001683168-26-006493 index |
| 2026-08-14 | 10-Q | All annual, quarterly, and current reports | 2026-06-30 | 0001683168-26-006472 index |
| 2026-07-17 | 8-K | All annual, quarterly, and current reports | 2026-07-15 | 0001683168-26-005616 index |
| 2026-06-08 | DRS | Registration statements and prospectuses | no report period | 0001683168-26-004622 index |
| 2026-05-22 | 8-K | All annual, quarterly, and current reports | 2026-05-21 | 0001683168-26-004268 index |
| 2026-05-22 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-05-21 · transaction | 0001683168-26-004260 index |
| 2026-05-22 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-05-21 · transaction | 0001683168-26-004257 index |
| 2026-05-22 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-05-21 · transaction | 0001683168-26-004255 index |
| 2026-05-22 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-05-21 · transaction | 0001683168-26-004251 index |
| 2026-05-22 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-05-21 · transaction | 0001683168-26-004245 index |
| 2026-05-22 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-05-21 · transaction | 0001683168-26-004243 index |
| 2026-05-22 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-05-21 · transaction | 0001683168-26-004241 index |
| 2026-05-14 | S-8 | Registration statements and prospectuses | no report period | 0001683168-26-003915 index |
| 2026-05-14 | 10-Q | All annual, quarterly, and current reports | 2026-03-31 | 0001683168-26-003909 index |
| 2026-05-11 | 8-K | All annual, quarterly, and current reports | 2026-05-11 | 0001683168-26-003684 index |
| 2026-05-06 | 3 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-05-01 | 0001683168-26-003533 index |
| 2026-05-06 | DEFA14A | Proxy materials | no report period | 0001683168-26-003517 index |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 50.00K | 1 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 1.62M | 1 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| BIOS Capital Management, LP | 42.00% |
| Voss Capital, LP | 7.21% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.64% |
| Palogic Value Management, L.P. | 0.84% |
| AQR CAPITAL MANAGEMENT LLC | 0.53% |
| GEODE CAPITAL MANAGEMENT, LLC | 0.43% |
| Texas Capital Bank Wealth Management Services Inc | 0.43% |
| MILLENNIUM MANAGEMENT LLC | 0.40% |
| BlackRock, Inc. | 0.38% |
| ABS Investment Management LLC | 0.31% |
Funds
| Fund | % owned |
|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 1.20% |
| VANGUARD EXTENDED MARKET INDEX FUND | 0.44% |
| Fidelity Small Cap Index Fund | 0.39% |
| Fidelity Extended Market Index Fund | 0.27% |
| VANGUARD RUSSELL 2000 INDEX FUND | 0.20% |
| iShares Micro-Cap ETF | 0.16% |
| Ultra-Small Company Market Fund | 0.10% |
| Schwab Small-Cap Index Fund | 0.08% |
| Fidelity Total Market Index Fund | 0.06% |
| iShares Russell 2000 ETF | 0.06% |
OakChart. ACTU. Cached 15 minutes. Terms